Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Cancer cells alter metabolic processes to sustain their characteristic uncontrolled growth
and proliferation. These metabolic alterations include (1) a shift from oxidative …

Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

Metabolic reprogramming is a hallmark of cancer and allows tumour cells to meet the
increased energy demands required for rapid proliferation, invasion, and metastasis …

Simple Summary Reprogramming of glucose metabolism is a hallmark of cancer and can be
targeted by therapeutic agents. Some metabolism regulators, such as ivosidenib and …

Somatic point mutations at a key arginine residue (R132) within the active site of the
metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in …

Metabolic inhibitors have been used in oncology for decades, dating back to antimetabolites
developed in the 1940s. In the past 25 years, there has been increased recognition of …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …

The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations
across multiple cancer types including both solid and hematologic malignancies has …